CN105193809B - 用于治疗运动障碍的血清素受体激动剂组合物 - Google Patents

用于治疗运动障碍的血清素受体激动剂组合物 Download PDF

Info

Publication number
CN105193809B
CN105193809B CN201510595196.8A CN201510595196A CN105193809B CN 105193809 B CN105193809 B CN 105193809B CN 201510595196 A CN201510595196 A CN 201510595196A CN 105193809 B CN105193809 B CN 105193809B
Authority
CN
China
Prior art keywords
days
receptor
combination
dyskinesia
buspirone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201510595196.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN105193809A (zh
Inventor
J·B·汉森
M·S·汤姆森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CONCIT PHARMA APS
Original Assignee
CONCIT PHARMA APS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CONCIT PHARMA APS filed Critical CONCIT PHARMA APS
Publication of CN105193809A publication Critical patent/CN105193809A/zh
Application granted granted Critical
Publication of CN105193809B publication Critical patent/CN105193809B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201510595196.8A 2010-10-15 2011-10-13 用于治疗运动障碍的血清素受体激动剂组合物 Active CN105193809B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US39354510P 2010-10-15 2010-10-15
DKPA201070441 2010-10-15
US61/393,545 2010-10-15
DKPA201070441 2010-10-15
US201161491945P 2011-06-01 2011-06-01
US61/491,945 2011-06-01
CN201180060726.9A CN103402514B (zh) 2010-10-15 2011-10-13 用于治疗运动障碍的血清素受体激动剂组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201180060726.9A Division CN103402514B (zh) 2010-10-15 2011-10-13 用于治疗运动障碍的血清素受体激动剂组合物

Publications (2)

Publication Number Publication Date
CN105193809A CN105193809A (zh) 2015-12-30
CN105193809B true CN105193809B (zh) 2019-07-16

Family

ID=44883032

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510595196.8A Active CN105193809B (zh) 2010-10-15 2011-10-13 用于治疗运动障碍的血清素受体激动剂组合物
CN201180060726.9A Active CN103402514B (zh) 2010-10-15 2011-10-13 用于治疗运动障碍的血清素受体激动剂组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201180060726.9A Active CN103402514B (zh) 2010-10-15 2011-10-13 用于治疗运动障碍的血清素受体激动剂组合物

Country Status (22)

Country Link
US (2) US9186359B2 (https=)
EP (1) EP2627328B1 (https=)
JP (1) JP5907975B2 (https=)
KR (1) KR101825972B1 (https=)
CN (2) CN105193809B (https=)
AU (1) AU2011316225B2 (https=)
BR (1) BR112013009004B1 (https=)
CA (1) CA2813648C (https=)
CY (1) CY1118314T1 (https=)
DK (1) DK2627328T3 (https=)
ES (1) ES2602973T3 (https=)
HR (1) HRP20161402T1 (https=)
HU (1) HUE031661T2 (https=)
IL (1) IL225758A (https=)
LT (1) LT2627328T (https=)
MX (1) MX353625B (https=)
PL (1) PL2627328T3 (https=)
PT (1) PT2627328T (https=)
RS (1) RS55332B1 (https=)
RU (1) RU2611376C2 (https=)
SI (1) SI2627328T1 (https=)
WO (1) WO2012048710A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2714040A1 (en) * 2011-06-01 2014-04-09 Concit Pharma ApS Combinations of serotonin receptor agonists for treatment of movement disorders
NZ700474A (en) 2012-04-18 2016-10-28 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders
EP2858649B1 (en) * 2012-06-11 2019-10-23 Psychogenics Inc. Treatment of motor and movement disorder side effects associated with parkinson's disease treatments
PT3160464T (pt) 2014-06-26 2018-10-12 Contera Pharma Aps 6-hidroxibuspirona para uso no tratamento de transtornos do movimento
ES2668379T3 (es) * 2014-07-09 2018-05-17 Pierre Fabre Médicament Método para el tratamiento de trastornos del movimiento con befiradol
WO2016210431A1 (en) * 2015-06-26 2016-12-29 Wright State University Method of treating sepsis-induced myopathy
US11013830B2 (en) * 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
AU2017297718B2 (en) 2016-07-11 2023-06-08 Contera Pharma A/S Pulsatile drug delivery system for treating morning akinesia
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
EP4335504A3 (en) 2018-12-20 2024-05-29 Contera Pharma A/S Treatment of movement disorders
WO2021127391A1 (en) 2019-12-20 2021-06-24 The Jackson Laboratory Molecular targets for addiction
CN112931397B (zh) * 2021-01-25 2024-02-27 江南大学 一种帕金森病动物模型的构建方法
US20240216356A1 (en) * 2021-05-07 2024-07-04 Eli Lilly And Company Taste masked compostions of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and orally disentegrating tablet comprising the same
CN114712365B (zh) * 2022-06-07 2022-08-23 山东绿叶制药有限公司 Trk抑制剂在制备治疗迟发性运动障碍药物中的应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759371A (fr) 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
US3976776A (en) 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4182763A (en) 1978-05-22 1980-01-08 Mead Johnson & Company Buspirone anti-anxiety method
US4356108A (en) 1979-12-20 1982-10-26 The Mead Corporation Encapsulation process
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4438119A (en) 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
US4640921A (en) 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
US4687772A (en) 1986-10-07 1987-08-18 Bristol-Myers Company Method for improvement of short term memory
US4777173A (en) 1987-03-25 1988-10-11 Bristol-Myers Company Method for treatment of alcohol abuse
US5185329A (en) 1988-08-30 1993-02-09 Bristol-Myers Squibb Company Method for treatment of substance addiction
US6432956B1 (en) 1990-02-12 2002-08-13 William C. Dement Method for treatment of sleep apneas
PT97888B (pt) 1990-06-07 1998-12-31 Zeneca Ltd Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5431922A (en) 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
GB9209882D0 (en) 1992-05-07 1992-06-24 Glaxo Lab Sa Compositions
US5484788A (en) 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5637314A (en) 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
US6150365A (en) 1999-08-05 2000-11-21 Bristol-Myers Squibb Company Anxiety method
GB9928578D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations
ATE374192T1 (de) * 2000-11-29 2007-10-15 Lilly Co Eli 1-(2-m-methansulfonamidophenylethyl)-4-(m- trifluoromethylphenyl)piperazine und ihre akzeptablen pharmazeutischen salze und solvate und ihre verwendung zur behandlung von inkontinenz
AU2002241565A1 (en) * 2001-01-05 2002-07-16 Eli Lilly And Company Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
BR0212199A (pt) * 2001-09-12 2004-10-05 Merck Patent Gmbh Uso de aminometil cromanos substituìdos no tratamento de distúrbios do movimento
DE10353657A1 (de) * 2003-11-17 2005-06-23 Merck Patent Gmbh Indolderivate
EP1711493A2 (en) 2004-02-06 2006-10-18 CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement Crystalline forms of zolmitriptan
BRPI0514983A (pt) * 2004-09-07 2008-07-01 Pfizer combinação de um agonista do receptor 5-ht(1) e um ligante alfa-2-delta para tratamento da enxaqueca
US9066903B2 (en) 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
KR20090033871A (ko) * 2006-06-16 2009-04-06 솔베이 파마슈티칼스 비. 브이 비페프루녹스 및 ｌ-ｄｏｐａ를 포함하는 병용 제제
WO2008039514A1 (en) * 2006-09-26 2008-04-03 Cytrx Corporation Pharmaceutical compositions and methods for treating diseases associated with neurodegeneration
WO2008047839A1 (en) * 2006-10-19 2008-04-24 Dainippon Sumitomo Pharma Co., Ltd. 5-ht1a receptor agonist
US20080226715A1 (en) * 2007-03-16 2008-09-18 Albert Cha Therapeutic compositions and methods
CN101686942B (zh) 2007-06-27 2012-09-26 韩美药品株式会社 用于快速制备用于口服的崩解剂的方法及其产品
US20110183995A1 (en) 2008-06-24 2011-07-28 Neurosearch A/S Eltoprazine for suppression of l-dopa induced dyskinesias
JP2012505878A (ja) 2008-10-14 2012-03-08 マクニール アーベー 複数部分口内剤形及びその使用
WO2010084038A1 (en) 2009-01-23 2010-07-29 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Controlled release pharmaceutical or food formulation and process for its preparation
IN2012DN04858A (https=) * 2009-12-23 2015-09-25 Map Pharmaceuticals Inc
EP2714040A1 (en) 2011-06-01 2014-04-09 Concit Pharma ApS Combinations of serotonin receptor agonists for treatment of movement disorders

Also Published As

Publication number Publication date
PL2627328T3 (pl) 2017-03-31
BR112013009004A8 (pt) 2017-12-26
BR112013009004A2 (pt) 2016-07-05
RU2611376C2 (ru) 2017-02-21
CN103402514B (zh) 2016-01-13
IL225758A (en) 2017-03-30
CN103402514A (zh) 2013-11-20
KR20130101545A (ko) 2013-09-13
AU2011316225A1 (en) 2013-04-18
MX353625B (es) 2018-01-22
ES2602973T3 (es) 2017-02-23
EP2627328A1 (en) 2013-08-21
JP5907975B2 (ja) 2016-04-26
PT2627328T (pt) 2016-11-23
DK2627328T3 (en) 2016-12-12
CA2813648A1 (en) 2012-04-19
JP2013539767A (ja) 2013-10-28
US20130252965A1 (en) 2013-09-26
US9186359B2 (en) 2015-11-17
BR112013009004B1 (pt) 2022-05-10
WO2012048710A1 (en) 2012-04-19
EP2627328B1 (en) 2016-09-14
LT2627328T (lt) 2016-11-25
AU2011316225B2 (en) 2016-05-19
HUE031661T2 (en) 2017-07-28
KR101825972B1 (ko) 2018-02-06
US10632116B2 (en) 2020-04-28
SI2627328T1 (sl) 2017-01-31
RS55332B1 (sr) 2017-03-31
IL225758A0 (en) 2013-06-27
RU2013120481A (ru) 2014-11-20
MX2013004067A (es) 2013-07-29
CA2813648C (en) 2019-06-25
US20160058762A1 (en) 2016-03-03
CN105193809A (zh) 2015-12-30
CY1118314T1 (el) 2017-06-28
HRP20161402T1 (hr) 2016-12-30

Similar Documents

Publication Publication Date Title
CN105193809B (zh) 用于治疗运动障碍的血清素受体激动剂组合物
US9700548B2 (en) Antihistamines combined with dietary supplements for improved health
US20170056379A1 (en) Method of using dopamine reuptake inhibitors and their analogs for treating diabetes symptoms and delaying or preventing diabetes-associated pathologic conditions
US20140241990A1 (en) Methods of using adenosine a1 receptor activation for treating depression
US20140243350A1 (en) Use of serotonin receptor agonists for treatment of movement disorders
US20140221385A1 (en) Combinations of serotonin receptor agonists for treatment of movement disorders
EP2145620A2 (en) Gaboxadol for treating depression and other affective disorders
CN107635555A (zh) 丁螺环酮代谢物的用途
US20050234093A1 (en) Treatment of depression and other affective disorders
US20240284941A1 (en) Antihistamines combined with dietary supplements for improved health
EP4670736A1 (en) PHARMACEUTICAL PRODUCT FOR THE TREATMENT OR PREVENTION OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY
HK1188927B (en) Combinations of serotonin receptor agonists for treatment of movement disorders
Birkmayer et al. The clinical pathology of Parkinson’s disease
TW200524920A (en) Treatment of circadian rhythm disorders with NPY Y5 receptor antagonist

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant